Table 22Risk of fracture for menopausal estrogen therapy, relative to placebo, by fracture group

Author, YearStudy DurationType of FractureNumber of Fractures, EstrogenNumber of Fractures, Placebo or ControlOdds Ratio (95% CI)
All Fractures
Original 2007 report
Bone, 20005824 monthsAny clinical10/1434/500.86 (0.25, 2.97)
Greenspan, 20035936 monthsClinical5/939/930.54 (0.18, 1.60)
Update Report: No new studies
Vertebral Fractures
Original 2007 Report
Ishida, 200413724 monthsVertebral7/66*17/660.36 (0.15, 0.88)
Reid, 200412236 monthsVertebral1/1021/900.88 (0.05, 14.27)
Wimalawansa, 199813848 monthsVertebral2/15*5/140.31 (0.06, 1.64)
Update Report
Boone, 200613624 monthsVertebral0/162/150.12 (.01, 1.98)
Nonvertebral Fractures
Original 2007 Report
Wimalawansa, 199813848 monthsNonvertebral1/15*1/140.93 (0.06, 15.69)
Update Report
Boone, 200613624 monthsNonvertebral0/160/15NC

NC = not calculable

*

Bone, 2000: conjugated equine estrogen; Greenspan, 2003: conjugated equine estrogen±medroxyprogesterone acetate; Reid, 2004: conjugated equine estrogen; Wimalawansa, 1998: conjugated equine estrogen+norgestrel; Boon, 2006: combination topical (patch) estradiol+norethindrone acetate.

Control group.

From: Results

Cover of Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report
Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: Update of a 2007 Report [Internet].
Comparative Effectiveness Reviews, No. 53.
Crandall CJ, Newberry SJ, Diamant A, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.